Literature DB >> 6088797

Immunity in the female genital tract after intravaginal vaccination of mice with an attenuated strain of herpes simplex virus type 2.

M R McDermott, J R Smiley, P Leslie, J Brais, H E Rudzroga, J Bienenstock.   

Abstract

Herpes simplex virus type 2 is a common human venereal pathogen which causes lethal neurological illness after intravaginal inoculation into BALB/cJ mice. To investigate whether an attenuated, nonlethal strain of this virus would confer immunity after inoculation of mice, we constructed a strain containing a partial deletion of the thymidine kinase gene, which is necessary for viral replication and spread in sensory ganglia. Unlike its wild-type counterpart, this deletion-containing strain of herpes simplex virus type 2 caused mild clinical disease and was not lethal when studied in an age-dependent murine model of intravaginal infection. Furthermore, after intravaginal infection, the deletion-containing strain could not be isolated from sensory ganglia at a time when wild-type virus was abundant. Of greater significance, intravaginal inoculation with the deletion-containing strain rendered mice completely resistant to rechallenge with a 10-fold 50% lethal dose of wild-type virus. These results suggest that a strain of herpes simplex virus type 2 containing a deletion of the thymidine kinase gene will be useful in studying the cellular basis of mucosal immunity in the genital tract.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6088797      PMCID: PMC255840     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Selective extraction of polyoma DNA from infected mouse cell cultures.

Authors:  B Hirt
Journal:  J Mol Biol       Date:  1967-06-14       Impact factor: 5.469

2.  Concept review of genital herpes vaccines.

Authors:  W P Allen; F Rapp
Journal:  J Infect Dis       Date:  1982-03       Impact factor: 5.226

3.  Acute and recurrent herpes simplex in several strains of mice.

Authors:  D A Harbour; T J Hill; W A Blyth
Journal:  J Gen Virol       Date:  1981-07       Impact factor: 3.891

4.  Protection against lethal challenge of BALB/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex virus type 2.

Authors:  N Balachandran; S Bacchetti; W E Rawls
Journal:  Infect Immun       Date:  1982-09       Impact factor: 3.441

5.  Alteration of rabbit alveolar and peritoneal macrophage function by herpes simplex virus.

Authors:  S Plaeger-Marshall; L A Wilson; J W Smith
Journal:  Infect Immun       Date:  1983-09       Impact factor: 3.441

Review 6.  The structural basis for immunity in the respiratory tract.

Authors:  M R McDermott; A D Befus; J Bienenstock
Journal:  Int Rev Exp Pathol       Date:  1982

7.  Transfection with the isolated herpes simplex virus thymidine kinase genes. I. Minimal size of the active fragments from HSV-1 and HSV-2.

Authors:  G R Reyes; K T Jeang; G S Hayward
Journal:  J Gen Virol       Date:  1982-10       Impact factor: 3.891

8.  Protection of mice from fatal herpes simplex virus type 1 infection by adoptive transfer of cloned virus-specific and H-2-restricted cytotoxic T lymphocytes.

Authors:  K K Sethi; Y Omata; K E Schneweis
Journal:  J Gen Virol       Date:  1983-02       Impact factor: 3.891

9.  Effect of prior immunization on induction of cervial cancer in mice by herpes simplex virus type 2.

Authors:  W B Wentz; A D Heggie; D D Anthony; J W Reagan
Journal:  Science       Date:  1983-12-09       Impact factor: 47.728

10.  Recovery from lethal herpes simplex virus type 1 infection is mediated by cytotoxic T lymphocytes.

Authors:  H S Larsen; R G Russell; B T Rouse
Journal:  Infect Immun       Date:  1983-07       Impact factor: 3.441

View more
  63 in total

1.  Interleukin-12 (IL-12) and IL-18 are important in innate defense against genital herpes simplex virus type 2 infection in mice but are not required for the development of acquired gamma interferon-mediated protective immunity.

Authors:  A M Harandi; B Svennerholm; J Holmgren; K Eriksson
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  Vaginal formulations of carrageenan protect mice from herpes simplex virus infection.

Authors:  V R Zacharopoulos; D M Phillips
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

3.  Vaccination of mice and swine with a pseudorabies virus mutant lacking thymidine kinase activity.

Authors:  M D McFarland; H T Hill
Journal:  Can J Vet Res       Date:  1987-07       Impact factor: 1.310

4.  Zinc acetate/carrageenan gels exhibit potent activity in vivo against high-dose herpes simplex virus 2 vaginal and rectal challenge.

Authors:  José A Fernández-Romero; Ciby J Abraham; Aixa Rodriguez; Larisa Kizima; Ninochka Jean-Pierre; Radhika Menon; Othell Begay; Samantha Seidor; Brian E Ford; Pedro I Gil; Jennifer Peters; David Katz; Melissa Robbiani; Thomas M Zydowsky
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

Review 5.  Local immunity and the uterine cervix: implications for cancer-associated viruses.

Authors:  J K Roche; C P Crum
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

6.  Rectal immunization for induction of specific antibody in the genital tract of women.

Authors:  P A Crowley-Nowick; M C Bell; R Brockwell; R P Edwards; S Chen; E E Partridge; J Mestecky
Journal:  J Clin Immunol       Date:  1997-09       Impact factor: 8.317

7.  Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus.

Authors:  T Muster; B Ferko; A Klima; M Purtscher; A Trkola; P Schulz; A Grassauer; O G Engelhardt; A García-Sástre; P Palese
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

8.  Long-term presence of virus-specific plasma cells in sensory ganglia and spinal cord following intravaginal inoculation of herpes simplex virus type 2.

Authors:  Gregg N Milligan; Michael G Meador; Chin-Fun Chu; Christal G Young; Talitha L Martin; Nigel Bourne
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

9.  Effector CD4+ T-cell involvement in clearance of infectious herpes simplex virus type 1 from sensory ganglia and spinal cords.

Authors:  Alison J Johnson; Chin-Fun Chu; Gregg N Milligan
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

10.  Antibody-mediated protection against genital herpes simplex virus type 2 disease in mice by Fc gamma receptor-dependent and -independent mechanisms.

Authors:  Chin-Fun Chu; Michael G Meador; Christal G Young; Jane E Strasser; Nigel Bourne; Gregg N Milligan
Journal:  J Reprod Immunol       Date:  2007-10-24       Impact factor: 4.054

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.